Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0263
View Point
|
Predicting risk of disease and therapeutic resistance for patients with Hepatocellular Carcinoma. |
Dimitrios Schizas, MD, PhD.
|
Affiliation: Dimitrios Schizas, (DS), 1st Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Tel:+302651005571
E-mail: schizasad@gmail.com |
Abstract
Prognosis of hepatocellular carcinoma (HCC) remains poor. The slow progress in understanding the molecular mechanisms driving tumorigenesis, metastasis and therapeutic resistance explains the low rates of early detection and overall survival. This editorial summarizes the latest advances and challenges of next-generation sequencing (NGS) in developing robust biomarkers to predict the individualized risk and therapeutic response of HCCs.
(Citation: Gastric & Breast Cancer 2017; 12(2): 85-90)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
